Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: A population-based study

The Lancet Haematology

Volumn 2, Issue 10, 2015, Pages e445-e455

  Keane, Colm ^a,b,c   Vari, Frank ^a   Hertzberg, Mark ^d   Cao, Kim Anh Lê ^a   Green, Michael R ^e   Han, Erica ^a   Seymour, John F ^f   Hicks, Rodney J ^f   Gill, Devinder ^a,b   Crooks, Pauline ^a   Gould, Clare ^a,b   Jones, Kimberley ^a   Griffiths, Lyn R ^c   Talaulikar, Dipti ^g,h   Jain, Sanjiv ^g   Tobin, Josh ^h   Gandhi, Maher K ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c GRIFFITH UNIVERSITY   (Australia)

^d PRINCE OF WALES HOSPITAL   (Australia)

^e UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^f PETER MACCALLUM CANCER CENTRE   (Australia)

^g CANBERRA HOSPITAL   (Australia)

^h The Australian National University   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE; BIOLOGICAL MARKER; CD137 ANTIGEN; CD163 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PREDNISONE; R-CHOP PROTOCOL;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; CANCER PROGNOSIS; CANCER SURVIVAL; CD4 CD8 RATIO; CELL CYCLE CHECKPOINT; CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; IMMUNOSURVEILLANCE; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA EXTRACTION; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; AUSTRALIA; IMMUNOLOGY; LYMPHOMA, LARGE B-CELL, DIFFUSE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PROGNOSIS; QUEENSLAND; SURVIVAL RATE; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD274; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUSTRALIA; BIOMARKERS; CD4-CD8 RATIO; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; KILLER CELLS, NATURAL; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; QUEENSLAND; SURVIVAL RATE; T-LYMPHOCYTES; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 84955297987     PISSN: None     EISSN: 23523026     Source Type: Journal    
DOI: 10.1016/S2352-3026(15)00150-7     Document Type: Article

References (40)

1. Coiffier B. State-of-the-art therapeutics: diffuse large B-cell lymphoma. J Clin Oncol 2005; 23: 6387-93.
2. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-11.
3. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109: 1857-61.
4. Tran H, Nourse J, Hall S, et al. Immunodeficiency-associated lymphomas. Blood Rev 2008; 22: 261-81.
5. Afshar-Sterle S, Zotos D, Bernard NJ, et al. Fas ligand-mediated immune surveillance by T cells is essential for the control of spontaneous B cell lymphomas. Nat Med 2014; 20: 283-90.
6. Gandhi MK, Wilkie GM, Dua U, et al. Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders. Am J Transplant 2007; 7: 1293-99.
7. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-67.
8. Wilcox RA, Wada DA, Ziesmer SC, et al. Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells. Blood 2009; 114: 2936-44.
9. Keane C, Gill D, Vari F, et al. CD4(+) tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy. Am J Hematol 2013; 88: 273-76.
10. Li ZM, Huang JJ, Xia Y, et al. Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP. PLoS One 2012; 7: e41658.
11. Porrata LF, Ristow K, Habermann TM, et al. Absolute monocyte/lymphocyte count prognostic score is independent of immunohistochemically determined cell of origin in predicting survival in diffuse large B-cell lymphoma. Leuk Lymphoma 2012; 53: 2159-65.
12. Obermajer N, Muthuswamy R, Lesnock J, et al. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells towards stable myeloid-derived suppressor cells. Blood 2011; 118: 5498-505.
13. Tadmor T, Fell R, Polliack A, et al. Absolute monocytosis at diagnosis correlates with survival in diffuse large B-cell lymphoma-possible link with monocytic myeloid-derived suppressor cells. Hematol Oncol 2012; 31: 65-71.
14. Lin Y, Gustafson MP, Bulur PA, et al. Immunosuppressive CD14+HLA-DRlow/-monocytes in B-cell non-Hodgkin lymphoma. Blood 2011; 117: 872-81.
15. Challa-Malladi M, Lieu YK, Califano O, et al. Combined genetic inactivation of ß2-microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell 2011; 20: 728-40.
16. Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008; 359: 2313-23.
17. Adams DL, Martin SS, Alpaugh RK, et al. Circulating giant macrophages as a potential biomarker of solid tumors. Proc Natl Acad Sci USA 2014; 111: 3514-19.
18. Monti S, Savage KJ, Kutok JL, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005; 105: 1851-61.
19. Alvaro T, Lejeune M, Escriva P, et al. Appraisal of immune response in lymphoproliferative syndromes: a systematic review. Crit Rev Oncol Hematol 2009; 70: 103-13.
20. Norris S, Coleman A, Kuri-Cervantes L, et al. PD-1 expression on natural killer cells and CD8(+) T cells during chronic HIV-1 infection. Viral Immunol 2012; 25: 329-32.
21. Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4: 127ra37.
22. Armand P, Nagler A, Weller EA, et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol 2013; 31: 4199-206.
23. Geiss GK, Bumgarner RE, Birditt B, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 2008; 26: 317-25.
24. Masque-Soler N, Szczepanowski M, Kohler CW, et al. Molecular classification of mature aggressive B-cell lymphoma using digital multiplexed gene expression on formalin-fixed paraffin-embedded biopsy specimens. Blood 2013; 122: 1985-86.
25. Scott DW, Wright GW, Williams PM, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin embedded tissue. Blood 2014; 123: 1214-17.
26. Ye Q, Song DG, Poussin M, et al. CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin Cancer Res 2014; 20: 44-55.
27. Jones K, Nourse JP, Morrison L, et al. Expansion of EBNA1-specific effector T cells in posttransplantation lymphoproliferative disorders. Blood 2010; 116: 2245-52.
28. Jones K, Vari F, Keane C, et al. Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma. Clin Cancer Res 2013; 19: 731-42.
29. Rossille D, Gressier M, Damotte D, et al. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-cell lymphoma: results from a French multicenter clinical trial. Leukemia 2014; 28: 2367-75.
30. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 1995; 57: 289-300.
31. Nam SJ, Go H, Paik JH, et al. An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. Leuk Lymphoma 2014; 55: 2466-76.
32. Rimsza LM, Wright G, Schwartz M, et al. Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues. Clin Cancer Res 2011; 17: 3727-32.
33. Wilcox RA, Ristow K, Habermann TM, et al. The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma. Leuk Lymphoma 2012; 53: 575-80.
34. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-64.
35. Gandhi MK, Lambley E, Duraiswamy J, et al. Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients. Blood 2006; 108: 2280-89.
36. Elstrom RL, Martin P, Leonard JP. New biologic agents and immunologic strategies. Hematol Oncol Clin North Am 2008; 22: 1037-49.
37. Graversen JH, Svendsen P, Dagnaes-Hansen F, et al. Targeting the hemoglobin scavenger receptor CD163 in macrophages highly increases the anti-inflammatory potency of dexamethasone. Mol Ther 2012; 20: 1550-58.
38. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515: 568-71.
39. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372: 311-19.
40. Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014; 20: 5064-74.